Immunoglobulin E specific for Bet v 1 (Bet v 1-sIgE)

Immunoglobulin E (IgE) specific for Bet v 1 is the primary antibody responsible for Type I hypersensitivity reactions to birch pollen, which affects millions of individuals worldwide. Bet v 1 is the major allergen of Betula verrucosa (birch), and its specific IgE antibodies bind to high-affinity FcεRI receptors on the surface of mast cells and basophils. Upon subsequent exposure to birch pollen, Bet v 1 cross-links these IgE molecules, triggering the rapid release of inflammatory mediators like histamine and leukotrienes, leading to symptoms of allergic rhinitis, asthma, and oral allergy syndrome. Therapeutic strategies targeting this molecule include broad anti-IgE monoclonal antibodies like omalizumab, which sequester free IgE, and allergen-specific immunotherapy (AIT), which aims to induce blocking IgG4 antibodies that compete with IgE for allergen binding. Emerging therapies also include allergen-specific IgG cocktails designed to rapidly neutralize Bet v 1 and prevent its interaction with IgE.

Other names

Birch pollen allergen-specific IgEAnti-Bet v 1 IgEsIgE Bet v 1Bet v 1-specific IgE

Neutralization of free IgE to prevent binding to FcεRI receptors; downregulation of FcεRI expression on effector cells; induction of IgG4 blocking antibodies that compete for allergen binding; direct neutralization of the Bet v 1 allergen to prevent IgE cross-linking.